Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hawthorn Mingzi
- Development stage
- Preclinical
- Administration
- Oral
01
Overview
Hawthorn Mingzi is a traditional Chinese medicine compound, often prepared as a solid drink, that combines hawthorn (Crataegus) and cassia seed (决明子, Jue Ming Zi). It is investigated for its potential to manage dyslipidemia, likely through mechanisms related to lipid metabolism and cardiovascular health. Both ingredients have a long history of use in traditional medicine for their beneficial effects on cardiovascular health and lipid profiles.
- Other names
- Hawthorn Mingzi Solid Drink山楂明子固体饮料
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)LDLR (Low-density lipoprotein receptor)LPL (Lipoprotein lipase)PPARA (Peroxisome proliferator-activated receptor alpha)SOAT1 (Sterol O-acyltransferase)
Beyond the preview
Go deeper on Hawthorn Mingzi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hawthorn Mingzi.